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Abstract: I n t r o d u c t i o n: Graves’ Disease (GD) is an autoimmune hyperthyroidism occurring mostly 
in young women. The main pathogenic role of the disease is attributed to TSH receptor antibodies 
(TRAb), which stimulate the thyroid gland to increase production of the most active thyroid hormone- 
triiodothyronine (T3). High level of TRAb and a large goiter size are commonly known as poor prognostic 
factors for the disease and are used to predict relapse. 
T h e  a i m: The purpose of our study was to check the correlation between fT3:fT4 ratio with TRAb 
concentration, total volume of thyroid and age of GD onset. 
M a t e r i a l s  a n d  M e t h o d s :  114 patients with onset or relapse of GD were analyzed. Those after 
thyroidectomy or radioiodine therapy were not taken into analysis. The data was retrospectively retrieved 
from the hospital’s records consisting of patients’ sex, age, level of TRAb, fT3, fT4 and thyroid volume on 
ultrasonography. The association between fT3:fT4 and TRAb concentration, thyroid volume and age was 
evaluated using Pearson correlation coefficient. 
R e s u l t s: The group was predominated by women (19.3% men, 80.7% women). The average age was 47.0. 
The analysis revealed positive correlation between: 1) fT3:fT4 ratio and total volume of thyroid (correla-
tion ratio: 0.37; p <0.05) 2) fT3:fT4 ratio and level of TRAb (correlation ratio: 0.26; p <0.05) 3) negative 
correlation between fT3:fT4 ratio and patient’s age (correlation ratio: –0.14; p = 0.144.Conclusions: 
Positive correlations between fT3:fT4 ratio and TRAb level and total volume of thyroid (poor predictors 
of GD) may confirm that high level of fT3 can also be a prognostic factor for GD severity. 
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Introduction 
Graves’ disease (GD) is a common autoimmune disorder in endocrinologist practice, 
that is a cause of 60–80% cases of thyrotoxicosis [1]. The disease is about 6 to 8 times 
more frequent in females than males [2]. It affects 2% of women and 0.2% of men [3]. 
The main pathogenetic elements of GD are thyrotropin receptor antibodies (TRAbs), 
which stimulate the growth and the function of the thyroid follicular cells, that in-
itiates an excessive production of thyroid hormones and goiter formation [4]. 
Risk factors of GD include genetic susceptibility and environmental triggers, such 
as smoking, viral/bacterial infection and chemicals [4]. The purpose of GD treatment 
is to decrease thyroid hormones synthesis through antithyroid drugs (ATDT), or to 
decrease thyroid tissue through radioactive iodine treatment (131-I) or surgical 
ablation [5].The ratio of total triiodothyronine (T3) to total thyroxine (T4) is 
a helpful index for the differentiation between GD and subacute thyroiditis [6]. How-
ever fT3 and fT4 are more widely used in clinical practice, because they are less 
dependent on thyroid hormone-binding proteins [6]. Due to numerous relapses 
and treatment failures, many researchers look for a better predictor of positive therapy 
outcome [1]. Known independent pretreatment predictors of GD therapy failure 
are higher TRAbs level and a larger goiter size at onset [4]. Furthermore patients less 
than 40 years old at onset have larger goiters and higher mean fT4 and fT3 con-
centration [7]. 
The aim of our study was to check the correlation in Graves’ disease between free 
triiodothyronine to free thyroxine ratio (fT3:fT4) with TRAB concentration, total 
volume of thyroid and age of GD onset. 
Materials and Methods 
The study represents a retrospective analysis of 114 patients with a first episode 
or relapse of GD , who were admitted to the Department of Endocrinology at the 
University Hospital in Cracow. The group was predominated by women (92 vs. 22). 
Patients who were treated with thyroidectomy or radioiodine were excluded from the 
study. The sources of the data were medical history (sex, age, type of hyperthyroid-
ism), physical examination (volume and dimensions of the thyroid measured in USG) 
and laboratory tests (concentrations of: fT3, fT4 and TRAb). The fT3:fT4 ratio was 
counted by dividing fT3 concentration by fT4 concentration.  
A hormonal assessment of serum fT4 (reference range: 12.0–22.0 pmol/L) and fT3 
(reference range: 3.1–6.8 pmol/L) was performed using electrochemiluminescent 
method and cobas pro 8000 analyzer (Roche Diagnostics, Basel, Switzerland). 
The concentration of anti TSH receptor (TRAb) antibodies (reference: <1U/L) was 
assessed by the radioimmunological method using highly sensitive Thermo Scientific 
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BRAHMS TRAK human RIA assay, (BRAHMS Diagnostic GmbH, Germany). 
All patients were tested using the same methods. 
Shapiro-Wilk test, Spearman rank correlation and U Mann-Whitney test were 
used for statistical analysis of the results. The Shapiro-Wilk test was used to check 
if the data was consistent with a normally distributed population. The Spearman rank 
correlation was used to estimate correlation between several parameters. The 
U Mann-Whitney test was used to compare patients with first episode of GD and 
relapse of GD. The probability <0.05 was considered statistically significant. Statistical 
analyses were performed using Statistica version 13 for Windows (Statsoft Polska). 
Our study is an analysis of retrospective data of hospitalized patients. Each patient 
signed consent for performing all tests, which is included in patients documentation. 
Results 
The distribution of the analyzed population was not normal. 
The group of patients consisted of 30 patients with a first episode of GD and 84 
patients with relapse of the disease. The group was predominated by women (80.7%). 
The baseline characteristics of the patients with Graves’ disease are presented in 
the Table 1. The median age of patients in the group with relapse was higher than in 
the group with first episode: 49.0 vs 39.5 years. The comparison of patients with first 
episode and the relapse of GD shows higher fT3 (15.73 pmol/L vs 16.71 pmol/L), fT4 
(40.01 pmol/L vs 42.88 pmol/L) and higher TRAb (15.31 U/L vs 19.61 U/L) as well as 
a larger goiter in patients with relapse. 
In the group of patients with relapse, in 16 patients with recurrence of hyperthyr-
oidism, it was not possible to clearly determine which recurrence it was. All of them 
were treated with anti-thyroid drugs for over 6 months. In the group of patients with 
relapses after ATDT withdrawal, the time from discontinuation of medication to the 
onset of relapse varied from 1 to 300 months. More detailed data were possible to be 
obtained in 68 of patients. Analysis of this group is presented in the Table 2. 
A positive correlations between fT3:fT4 ratio and TRAb concentration presents 
Fig. 1A-C. This correlation was found in the whole group, in the group with the first 
episode of GD as well as in the recurrent group. The strongest association was observed 
in the group with the first episode of GD (R = 0.46). All of these correlations were 
statistically significant (Table 3). 
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Table 1.  Characteristic of patients with Grave’s disease.   
Graves’ disease 
Total group 
(N = 114) 
Graves’ disease 
First episode 
(N = 30) 
Graves’ disease 
Relapse 
(N = 84) 
Age (years) 
Median, Min; Max 47.0 (18; 88) 39.5 (18; 79) 49.0 (18; 88) 
Male N (%) 22 (19.3) 3 (10) 19 (22.6) 
Female N (%) 92 (80.7) 27 (90) 65 (77.4) 
Thyroid volume (mL) 
Mean ± SD 31.62 ± 24.27 29.68 ± 23.21 32.32 ± 24.60 
Thyroid function tests 
fT3 (pmol/L) 
Mean ± SD 16.45 ± 10.26 15.73 ± 7.73 16.71 ± 11.00 
fT4 (pmol/L) 
Mean ± SD 42.12 ± 24.71 40.01 ± 20.02 42.88 ± 26.13 
TRAb (U/L) 
Mean ± SD 18.48 ± 15.80 15.31 ±16.25 19.61 ± 15.48 
fT3:fT4 
Mean ± SD 0.41 ± 0.19 0.43 ± 0.20 0.41 ± 0.19   
Table 2.  Analysis of subgroups of patients with relapse of Graves’ disease.  
Patients with relapse  
during ATDT 
Patients with relapse 
after ATDT withdrawal 
Number of patients 31 (women: 19) 37 (women: 33) 
Number of relapses One relapse: 31 
One relapse: 32 
Two relapses: 4 
Three relapses: 1 
Time to relapse after starting ATDT (months) Max: 36; Min: 1 x 
Time to relapse after starting ATDT in women 
group (months) Max: 24; Min: 1 x 
Time to relapse after starting ATDT in men 
group (months) Max: 36; Min: 1 x 
Time to relapse after ATDT withdrawal (months) x Max: 300; Min: 1 
Time to relapse after ATDT withdrawal in 
women group (months) x Max: 300; Min: 1 
Time to relapse after ATD withdrawal in men 
group (months) x Max: 8; Min: 1 
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Fig. 1. Positive correlation between fT3:fT4 ratio and TRAb concentration. A — the whole group, 
B — the first episode group, C — the recurrence group. 
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A positive correlation between fT3:fT4 ratio and total thyroid volume (Fig. 2A–C, 
Table 4) was observed. The strongest association was observed in the group with the 
recurrent GD (R = 0.46). The correlations in the whole group and in the recurrent 
group were statistically significant, whereas in the group with the first episode of GD 
was not statistically significant (Table 4). 
Moreover a negative association between fT3:fT4 ratio and age of GD onset was 
found in the whole group, in the first episode of GD as well as in the recurrent group 
(Fig. 3A–C). Nor of the correlations were statistically significant (Table 5). 
Table 3.  fT3:fT4 and TRAb correlation.  
Number of 
compared pairs 
fT3:fT4 (×10) and TRAb 
R Spearman p 
Whole group 114 0.264780 0.004414 
The first episode 30 0.461984 0.010164 
Recurrence 84 0.220875 0.043484 
Table 4.  fT3:fT4 and thyroid volume correlation.  
Number of 
compared pairs 
fT3:fT4 (×10) and thyroid volume 
R Spearman p 
Whole group 114 0.37231 0.00004 
The first episode 30 0.162716 0.390281 
Recurrence 84 0.463941 0.000009   
Table 5.  fT3:fT4 and age of onset GD correlation.  
Number of 
compared pairs 
fT3:fT4 (×10) and age of onset 
R Spearman p 
Whole group 114 –0.137665 0.144118 
The first episode 30 –0.052368 0.783447 
Recurrence 84 –0.139892 0.204381  
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Fig. 2. Positive correlation between fT3:fT4 ratio and thyroid volume. A — the whole group, B — the first 
episode group, C — the recurrence group. 
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Fig. 3. Negative correlation between fT3:fT4 ratio and age of GD onset. A — the whole group, B — the 
first episode group, C — the recurrence group. 
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Discussion 
There is no unequivocal treatment strategy for Graves’ Disease. The first line therapy 
in The United States of America is radioiodine therapy after initial pharmacological 
management of acute phase of hyperthyroidism [8]. On the other hand — in Europe 
and Japan, long-term Antithyroid Drug Treatment (ATDT), lasting 12–18 months 
plays a main role [8]. The average rate of relapse after ATDT is 30–60% within 
1–5years of discontinuation [4, 9]. The vast majority of recurrences occur in the first 
year after treatment [10]. This high rate of failure during treatment of GD indicates 
the need of accurate analysis of particular parameters among patients with different 
course of GD. It would create an opportunity to divide patients into several categories 
and choose the best strategy for treatment. Currently in Europe, all patients with GD 
are treated following the same algorithm regardless of the “resistance” to the conven-
tional therapy [8]. This means that even those who show unresponsiveness to the 
pharmacological treatment, are exposed to long-term ATDT. This connects with 
higher risk of side effects, as well as elevating the costs of ineffective treatment. It 
evolves the need for clarifications of precise predictors of poor outcome during 
ATDT. Then those patients could be managed by radical methods (radioiodine ther-
apy/surgery) after initial short time pharmacological treatment and they could be 
cured definitely just during the first episode of GD. 
There are lots of studies analyzing different predictors, but there is no unequivocal 
consensus indicating precisely the values of particular parameters. In our work we 
confirm positive correlation between fT3:fT4 ratio and TRAb concentration (Fig. 1), 
positive correlation between fT3:fT4 ratio and goiter size (Fig. 2), as well as a negative 
correlation between fT3:fT4 ratio and age of onset (but not statistically significant) 
(Fig. 3). The hypothesis that higher fT3:fT4 ratio, TRAb level, goiter size and lower age 
of GD onset are predictors of worse response to ATDT remain coherent with many 
other studies. In our work we checked correlation between particular parameters in 
relation with fT3:fT4 ratio, because fT3 level reflects severity of hyperthyroidism.  
TRAbs pose a major pathogenetic role in GD. They stimulate the thyroid gland, 
which contributes to elevation of triiodothyronine (T3) and thyroxine (T4) level as 
well as thyroid gland enlargement [4]. Moreover, TRAbs promote peripheral conver-
sion of T4 to the ten times more active T3 [10]. These facts indicate that level of TRAb 
may correlate positively with the severity of the disease. Several works show that level 
of TRAb measured at the onset of GD or at the end of treatment remain a predictor of 
poor outcome of GD [4, 9, 11–14]. Dalia Dauksiene et al. claim that TRAb higher than 
30.2 U/L at the onset of the disorder and higher than 12.97 U/L after ATDT with-
drawal suggest insensitivity to pharmacological treatment [5].  
The goiter size as a further predictor of poor response to ATDT is mentioned in 
several articles [1, 4, 5, 9, 15, 16]. Some of them point precise thyroid volume of more 
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than 40 mL [3], the others suggest grade II and III (according to the WHO classifica-
tion) as an indicator of severe GD [1, 4]. Bjorn et al. claim that thyroidal hypoecho-
genicity on ultrasonography after ATDT discontinuation means active GD, contrast-
ing with the ultrasonographic images at the onset of GD, which cannot be interpreted 
as a poor predictor [4, 9, 16, 17]. Vitti et al. revealed that thyroid hypoechogenicity on 
ultrasonography is closely associated with TRAb and TSH level [16]. 
Despite this higher fT3:fT4 ratio at the onset of GD is pointed out as a bad 
predictor of GD [1, 10], as there are not any accurate values above which unrespon-
siveness to pharmacological treatment can be confirmed. We found articles measuring 
this rate in regard to distinguishing different kinds of hyperthyroidism [6, 18] — but 
there are also some discrepancies, because the units of hormone levels are different in 
different studies, and the disambiguation is necessary. 
Some authors suggest that continued TSH suppression after ATDT cessation 
predicts failure of pharmacological management. Prolonged TSH inhibition may in-
dicate subclinical hyperthyroidism [5, 19]. 
Smoking [9, 20] and onset at a younger age also are pointed out in several articles 
as poor response to ATDT [7, 9]. Aizawa et al. mention that TRAb level and the 
severity of GD diminish with age [21]. 
The next question is: could modification of pharmacological approach influences 
the rate of relapses? The literature confirm that levothyroxine (LT4) added to ATDT 
(block and replacement) as well as LT4 supplementation after ATDT shows no differ-
ences in the results of treatment [4, 9, 22]. The philosophy of these approaches was 
explained by the thesis that exogenous suppression of TSH by synthetic thyroxine may 
put the thyroid gland in a resting state, reducing the risk of relapse due to stimulation 
by TSH. Despite this logical explanation, several works didn’t prove the superiority of 
adding LT4 to the conventional pharmacological treatment of GD. Also a time 
of ATDT longer than 18 months doesn’t contribute to better outcomes of treatment 
[1, 4]. 
Conclusions 
Graves’ Disease is associated with a high rate of relapses. The standard of management 
in Europe is the same for all patients, regardless of the existence of several factors 
considered as indicators for poor response to pharmacological therapy. 
GD patients have a positive correlation between fT3:fT4 ratio and TRAB concen-
tration, fT3:fT4 ratio and thyroid volume at the moment of thyrotoxicosis. 
The fT3:fT4 ratio may be a predictor of an increased risk of relapse GD and may 
identify patients in whom early radical therapy would be beneficial to avoid bother-
some relapses. 
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